This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why AbbVie (ABBV) Could Beat Earnings Estimates Again
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie (ABBV) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $81.71 in the latest trading session, marking a -0.51% move from the prior day.
J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2020. It lowers its adjusted earnings and sales outlook for 2020 for coronavirus-related uncertainty. Stock up.
AstraZeneca's Koselugo Gets FDA Nod for Rare Genetic Disorder
by Zacks Equity Research
The FDA approves AstraZeneca (AZN) and Merck's kinase inhibitor, Koselugo, for treating pediatric patients with neurofibromatosis type 1 (NF1) having symptomatic, inoperable plexiform neurofibromas.
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
Should Value Investors Buy AbbVie (ABBV) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer
by Zacks Equity Research
Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
Want To Retire Early? Learn the Intelligent Investing Secret - April 09, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, QUALCOMM, PepsiCo and CME Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, QUALCOMM, PepsiCo and CME Group
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
Top Ranked Income Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 8th.
Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $75.27, marking a -0.61% move from the previous day.
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
Analyzing Coronavirus-Hit US Economy on World Health Day: 6 Picks
by Sweta Killa
Let us examine the health of the U.S. economy this World Health Day amid the ongoing COVID-19 crisis and bring to investors notice some solid picks for a robust investment portfolio.
Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
by Tirthankar Chakraborty
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Top Analyst Reports for Procter & Gamble, AbbVie & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), AbbVie (ABBV) and QUALCOMM (QCOM).
Another Drug to Fight Coronavirus & 3 Picks
by Sejuti Banerjea
Another drug is being tested to kill the virus (if we can figure out administration on humans).
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - April 06, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
The Extreme Risks of Trading Your Own Retirement Assets - April 02, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Powerful Proof Anyone Can Invest for an Early Retirement - April 01, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $76.11, moving +1.16% from the previous trading session.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
by Benjamin Rains
AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...